Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Mar;17(3):1649-1655.
doi: 10.3892/etm.2019.7147. Epub 2019 Jan 2.

Adenovirus-mediated herpes simplex virus thymidine kinase gene therapy combined with ganciclovir induces hepatoma cell apoptosis

Affiliations

Adenovirus-mediated herpes simplex virus thymidine kinase gene therapy combined with ganciclovir induces hepatoma cell apoptosis

Haitao Zhang et al. Exp Ther Med. 2019 Mar.

Abstract

The present study aimed to examine the apoptotic effects of adenovirus (ADV)-mediated herpes simplex virus thymidine kinase (ADV-TK) combined with ganciclovir (GCV) in tissues obtained from patients with hepatocellular carcinoma in order to provide a theoretical basis for the development of this gene therapy program. Apoptosis detection was conducted using the terminal deoxynucleotidyl-transferase-mediated dUTP nick end labelling assay and the apoptosis index was compared between the experimental; and control groups. Furthermore, the protein expression levels of caspase-3, B-cell lymphoma-2 (Bcl-2), Bcl-2-assoicated protein X (Bax) and nuclear factor (NF)-κB were examined in pathological specimens using immunohistochemical staining. The Bax/Bcl-2 ratio and the release of cytochrome c were examined using western blot analysis. Results indicated that combined ADV-TK and GCV treatment significantly increased the number of apoptotic cells compared with the control group (P<0.05). Immunohistological analysis revealed that ADV-TK and GCV treatment significantly increased the number of caspase-3-positive cells, reduced the Bax/Bcl-2 ratio and NF-κB expression levels and promoted the release of cytochrome c compared with the control group (P<0.01). In conclusion, the present results suggest that combined ADV-TK and GCV treatment exerts its effect through the apoptotic signaling pathway.

Keywords: apoptosis mechanism; gene therapy; hepatocellular carcinoma.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Combined adenovirus-mediated herpes simplex virus thymidine kinase and ganciclovir treatment induces hepatic cell apoptosis. (A) A TUNEL assay revealed apoptotic-positive hepatic cells marked by green staining. The blue DAPI staining marked intact DNA (magnification, ×400). (B) The apoptotic index was calculated. Data are presented as the mean ± standard deviation. TUNEL, terminal deoxynucleotidyl-transferase-mediated dUTP nick end labeling; DAPI, 4′6-diamidino-2-phenylindole.
Figure 2.
Figure 2.
Expression of apoptosis-associated proteins in tissues of patients with hepatocellular carcinoma detected by immunohistochemical staining and western blot analysis. (A) Image of positively stained cells and their localization in the combined ADV-TK and GCV treatment group and control groups. Analyses of (B) caspase-3, (C) Bax/Bcl-2 ratio and (D) NF-κB were performed in the combined ADV-TK and GCV treatment group and control group. (E) Representative images of western blot analysis. (F) Histogram of relative protein expression analysis. Data are presented as the mean ± standard deviation. **P<0.01 vs. control. ADV-TK, adenovirus-mediated herpes simplex virus thymidine kinase; GCV, ganciclovir; NF-κB, nuclear factor-κB; Bcl-2, B-cell lymphoma; Bax, B-cell lymphoma-associated protein X; Cyt C, cytochrome c; Cyto, cytosol; Mito, mitochondria.

Similar articles

Cited by

References

    1. Wallace MC, Preen D, Jeffrey GP, Adams LA. The evolving epidemiology of hepatocellular carcinoma: A global perspective. Expert Rev Gastroenterol Hepatol. 2015;9:765–779. doi: 10.1586/17474124.2015.1028363. - DOI - PubMed
    1. Kim NG, Nguyen PP, Dang H, Kumari R, Garcia G, Esquivel CO, Nguyen MH. Temporal trends in disease presentation and survival of patients with hepatocellular carcinoma: A real-world experience from 1998 to 2015. Cancer. 2018;124:2588–2598. doi: 10.1002/cncr.31373. - DOI - PubMed
    1. Libbrecht L, Desmet V, Roskams T. Preneoplastic lesions in human hepatocarcinogenesis. Liver Int. 2005;25:16–27. doi: 10.1111/j.1478-3231.2005.01016.x. - DOI - PubMed
    1. Faloppi L, Scartozzi M, Maccaroni E, Di Pietro Paolo M, Berardi R, Del Prete M, Cascinu S. Evolving strategies for the treatment of hepatocellular carcinoma: From clinical-guided to molecularly-tailored therapeutic options. Cancer Treat Rev. 2011;37:169–177. doi: 10.1016/j.ctrv.2010.08.001. - DOI - PubMed
    1. Rahbari NN, Mehrabi A, Mollberg NM, Müller SA, Koch M, Büchler MW, Weitz J. Hepatocellular carcinoma: Current management and perspectives for the future. Ann Surg. 2011;253:453–469. doi: 10.1097/SLA.0b013e31820d944f. - DOI - PubMed